Table 1. Major bleeding rates with... | American Society of Hematology

Table 1.

Major bleeding rates with extended treatment duration of at least 1 year in clinical trials with VKAs

Study	Reference	Duration of treatment, mo	Patients, n	Events, n	%
WODIT	10	12	134	4	3.0*
WODIT PE	11	12	165	3	1.8*
HOKUSAI VTE	12	12	1659	6	0.4*
REMEDY	13	≅15	1426	25	1.8†
PADIS	14	18	184	4	2.2‡
LAFIT	15	24	79	3	3.8*

Study	Reference	Duration of treatment, mo	Patients, n	Events, n	%
WODIT	10	12	134	4	3.0*
WODIT PE	11	12	165	3	1.8*
HOKUSAI VTE	12	12	1659	6	0.4*
REMEDY	13	≅15	1426	25	1.8†
PADIS	14	18	184	4	2.2‡
LAFIT	15	24	79	3	3.8*

Observation started at 3 mo from the index event.

Observation started after ∼6 mo from the index event.

Observation started at 6 mo from the index event.